SAN DIEGO, May 31, 2018 /PRNewswire/ — Denovo Biopharma LLC, a pioneer in using precision medicine to develop innovative therapies, today announced that Wen Luo, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Michael Haller, Ph.D., Chief Financial Officer, will be meeting with investors at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 in New York City.

Denovo Biopharma provides novel, proprietary biomarker approaches to personalized drug development, including re-evaluating drugs that failed in general patient populations. The company has the first platform for de novo genomic biomarker discovery using archived clinical samples. By retrospectively identifying biomarkers correlated with responses to drugs, Denovo enables clinical trials in targeted patient populations while optimizing efficacy, safety and tolerability. . (PRNewsFoto/Denovo Biomarkers)

About Denovo Biopharma

Denovo Biopharma is a clinical stage biopharmaceutical company that applies novel biomarker approaches to precision drug development to re-evaluate medicines that have failed in broad patient populations. The company applies its expertise to archived clinical samples to discover genomic biomarkers correlated with patients’ responses to drug candidates retrospectively. Denovo then designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo is enrolling patients in the U.S. and China with diffuse large B-cell lymphoma (DLBCL) in a Phase 3 clinical trial for its lead product candidate, DB102, which was in-licensed from Eli Lilly. The company has two additional late stage programs: DB103, for schizophrenia, and DB104, for depression. For additional information please visit


Robert H. Uhl
Managing Director
Westwicke Partners
(858) 356-5932


Cision View original content with multimedia:

SOURCE Denovo Biopharma LLC